By Melissa Rohman – NorthWwestern Medicine –
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet.
Marginal zone lymphoma (MZL) is a group of rare and slow-growing non-Hodgkin lymphomas that develop from B-cells and then spread into lymphoid tissues, including lymph nodes, as well as stomach tissue and bone marrow.
